Quoin Pharmaceuticals Reports $4.9 Million Q3 Loss and Positive QRX003 Interim Data
Quoin reported a $4.9 million net loss for the third quarter of 2026, versus $3.9 million a year earlier, and $33.2 million in cash, cash equivalents and investments at September-end. It also reported statistically significant interim results from its Phase 2 study of QRX003.
Quoin Pharmaceuticals reported a net loss of $4.9 million for the third quarter of 2026, compared with $3.9 million a year earlier, and ended September with $33.2 million in cash, cash equivalents and investments. The company also reported statistically significant interim results from its Phase 2…